Back to News
Market Impact: 0.3

PATH Crosses Above Average Analyst Target

PATHPrecision Optics Corporation, Inc.Acer Therapeutics Inc.Innovator ETFs Trust Innovator Equity Defined Protection ETF - OctoberNDAQ
Company FundamentalsAnalyst EstimatesAnalyst InsightsInvestor Sentiment & Positioning
PATH Crosses Above Average Analyst Target

UiPath Inc (PATH) shares have surpassed the average analyst 12-month target price of $16.36, now trading at $17.22/share, prompting a re-evaluation by investors and analysts. This development typically leads analysts to either raise targets due to fundamental improvements or consider valuation downgrades. The current consensus from 14 analysts, with targets ranging from $12.00 to $23.00 and an average rating of 2.56, suggests mixed views on its future trajectory, requiring investors to assess whether the current price signals further upside or a stretched valuation.

Analysis

UiPath Inc. (PATH) is at a critical inflection point, with its share price recently trading at $17.22, surpassing the average analyst 12-month price target of $16.36. This event forces a re-evaluation of the stock's valuation against its fundamentals. However, the analyst consensus is fractured, as evidenced by a wide dispersion in individual price targets, which range from a low of $12.00 to a high of $23.00, with a standard deviation of $3.078. The ratings breakdown further illustrates this division: while five analysts maintain a buy or strong buy rating, a significant majority of ten analysts have a 'Hold' rating, and one analyst holds a 'Strong Sell' position. Notably, the overall sentiment has slightly deteriorated over the last three months, with one 'Strong Buy' rating dropping off and the average rating shifting from 2.47 to 2.56, moving further from 'Buy' (2.0) towards 'Hold' (3.0). Therefore, the stock's recent price appreciation has occurred against a backdrop of cautious, rather than overwhelmingly bullish, analyst sentiment.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo